Skip to Main Content

Advertisement

Issue Archive

Table of Contents

Inside Blood

MYELOID NEOPLASIA

In this issue of Blood, Chou et al1  and Pulikkan et al2  reveal that the (8;21)(q22;q22) translocation product AML1-ETO (RUNX1-RUNX1T1) leads to enhanced JAK/STAT signaling downstream of myeloproliferative leukemia (MPL) virus, which in turn contributes to increased survival of tumor cells. Hijacking of the JAK/STAT pathway through up-regulation of wild-type MPL is a new paradigm for hematologic malignancies.

CLINICAL TRIALS

In this issue of Blood, Josephson et al report age group analyses of patients enrolled in the prophylactic platelet dose trial (PLADO) that evaluated the relationship between platelet dose per transfusion and bleeding in hospitalized patients with treatment-induced hypoproliferative thrombocytopenia.1 

THROMBOSIS & HEMOSTASIS

In this issue of Blood, Shibeko et al have used a variety of experimental studies and mathematical models to investigate the mechanism of action of high-dose factor VIIa as a bypassing agent in hemophilia.1 

Blood Work

Plenary Paper

MYELOID NEOPLASIA

Perspectives

Review Article

How I Treat

Clinical Trials and Observations

Immunobiology

Lymphoid Neoplasia

Myeloid Neoplasia

Phagocytes, Granulocytes, and Myelopoiesis

Thrombosis and Hemostasis

Transplantation

Vascular Biology

Errata

Other Departments

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement